IN the last I5 years chemotherapy has come to be recognized as playing an essential part in the palliative management of a few types of malignant disease. The natural and synthetic sex hormones and their derivatives are now in general use in the routine treatment of mammary and prostatic carcinoma; systemic chemotherapy by means of the so-called antimetabolites is the main form of treatment in the acute leukmmias; and the biological alkylating agents are equal in importance to radiotherapy in the treatment of the chronic leukemias, some malignant lymphomata, and generalized Hodgkin's disease. The place of systemic chemotherapy in these very restricted fields is generally acknowledged, but there is less agreement on its role in other and commoner forms of malignant disease. The value of the alkylating agents in the treatment of ovarian adenocarcinoma is becoming more widely known (Coonrad and Rundles, I959), but it is perhaps too early to define the precise indications for using them. It is unfortunate that many of the conditions in which chemotherapy is of most value are rarities, such as chorioncarcinoma, which may respond to the antimetabolites methotrexate and mercaptopurine (Buckle, (Vargha, I955) , was intended to improve the transport of the substance across cell membranes, while the incorporation of amino-acids as in phenylalanine nitrogen mustard (melphalan, sarcolysine) (Bergel and Stock, I954; Larionov, Khoklov, Shkodinskaja, Vasina, Troosheikina and Novikova, I955), and pyrimidines as in dopan (Larionov and Platonova, 1955) and uracil nitrogen mustard (Shanbrom, Miller, Opfell The selective uptake of these compounds would depend on differences in the distribution among the tissues of the enzyme necessary for splitting the molecule. The weakness of this approach is that there is no satisfactory evidence that malignant tissues contain any enzymes in higher concentrations than normal tissues. It is, however, possible, though unlikely, that a compound might be prepared requiring for its activation the agency of an enzyme not present in bone marrow cells. The major disadvantage of all the presently available alkylating agents is their toxicity to the hamopoietic cells; the synthesis of a compound relatively inactive against these cells would be a real advance, for none of the newer agents yet shows significant selectivity in its clinical effects. All function as typical nitrogen mustards, with only relatively minor quantitative differences from the original compound mustine. Some of these differences are of considerable clinical importance, comparable with those between rapidly-acting and slowly-acting barbiturates.
The Comparative Assessment of Chemotherapeutic Drugs
The comparative assessment of the value of a number of similar drugs is extremely difficult. Apparent differences may be due only to differences in the method of administration or in the relative size of the doses employed. The response to one compound may be long delayed, and by changing to a second compound too hurriedly the benefit eventually conferred may be erroneously attributed to the second drug. A drug may acquire a reputation of being especially useful in the treatment of a particular condition simply because it was, by chance, the first to have been tested on a large scale. Similar results might have been obtained had a different compound been chosen. Chronic lymphocytic leukwemia is a good example of a disease in which many different compounds have been claimed to be effective. Each of the following alkylating agents is in routine use at the present time at different centres: nitrogen mustard N-oxide (Nitromin), chlorambucil, mannomustine (Degranol), cyclophosphamide (Endoxan), 2-naphthylamine nitrogen mustard (R48), triethylenemelamine (TEM), triethylenethiophosphoramide (thio-TEPA, TSPA), bisethyleneiminobenzoquinone (E39), trisethyleneiminobenzoquinone (Trenimon). The similarity of the published results described for each of these compounds suggests that in chronic lymphocytic leukxmia the experience of the clinician is more important than the particular merits of the compounds. Each investigator becomes familiar with the effects of one or two drugs and is less likely to obtain equally good results with the drugs he has used less often.
Busulphan (Myleran) is widely believed to be the drug of choice for the treatment of chronic granulocytic leukamia (Dameshek and Gunz, 1958; Hayhoe, i960) , but equally good results have been claimed for many other alkylating agents, especially triethylenemelamine (Bethell, 1958) and trisethyleneiminobenzoquinone (Linke, I960), as well as for the purine antagonist, 6-mercaptopurine (Fountain, 1956 It is important to note that the doses of cytotoxic drugs cannot be increased indefinitely when administered by regional perfusion, even when leakage into the general circulation is negligible. This is because at high dose levels tissues other than the bone marrow are damaged, especially vascular endothelium, nerve, muscle and skin (private communication, Mr 
Conclusion
It is difficult to foresee the lines along which chemotherapy is likely to develop as long as we remain ignorant of the qualitative differences between normal and malignant cells. There seem to be many ways in which cells become malignant, and there are, as yet, no means of knowing whether a final common path is involved. Much experimental work on malignant disease, and especially experimental chemotherapy, necessarily proceeds on the assumption that all malignant growths share some common abnormality. If this difference from normal cells were known, a more rational approach to chemotherapy would be possible.
A major difficulty is that none of the available biological tests for potential chemotherapeutic agents provides a very reliable guide to the probable effects of the compounds on human malignant disease. The antimetabolites also show great differences in their toxicity for different animal species. Elion and her colleagues (Elion, Callahan, Hitchings and Rundles, i960) have shown that different species vary in their capacity to detoxicate mercaptopurine and related compounds.
Clinical trials have therefore to be carried out on an empirical basis, and it is not possible to infer from the results of experimental tests that one type of human malignant disease is more likely to respond than another. The use of fragments of human tumours, grown in tissue cultures or in the cheek pouches of hamsters, might seem to afford better material for testing chemotherapeutic agents than the transplanted or spontaneous animal tumours. The conditions under which the human tissues are grown and exposed to the drugs are, however, highly artificial and a great deal of critical work will have to be done if misleading conclusions are not to be drawn from this type of work. It is probable that a compound with exceptional tumour-inhibitory properties would be readily recognized by any of the commonly used methods of testing.
